Inpefa (Sotagliflozin)
Inpefa (Sotagliflozin)
- Medicine Name: Inpefa
- Generic Name: Sotagliflozin
- Dosage Form & Strength: Tablets: 200 mg and 400 mg
- Manufactured By: Lexicon Pharmaceuticals, Inc.
Inpefa (sotagliflozin) is an oral inhibitor of SGLT2 and SGLT1 used to scale down the risk of cardiovascular (CV) death, hospitalization for heart failure, and urgent heart failure (HF) visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular (CV) risk factors.
Recommended Dosage: The recommended starting dose of Inpefa tablet is 200 mg orally once daily not more than 60 minutes before the first meal of the day. Up-titrate dosage after at least 2 weeks to 400 mg orally once daily as tolerated. Down-titrate dosage to 200 mg as required. Swallow tablets whole. Avoid chewing, cutting, or crushing tablets.
For those with decompensated heart failure, dosing with Inpefa may begin as promptly as the patient is hemodynamically stable, including during urgent outpatient treatment or hospital stay or immediately upon discharge.
In case a dose is missed beyond six hours, take the very next scheduled dose as prescribed the next day.
- Ketone monitoring must be considered in those with type 1 diabetes mellitus and those at risk for ketoacidosis. Evaluate for ketoacidosis regardless of existing blood glucose levels and stop treatment in case ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis prior to restarting.
- Sotagliflozin pills can cause intravascular volume depletion which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. Prior to starting therapy in those with single or multiple of these characteristics, evaluate volume status and renal function. Monitor patients for signs and symptoms of renal function, and hypotension after starting this therapy.
- Treatment with Inpefa increases the probability of urinary tract infections. Critical urinary tract infections including pyelonephritis and urosepsis requiring hospital stay have been noticed. It is advised to evaluate patients for signs and symptoms of urinary tract infections and treat them quickly.
- Insulin and insulin secretagogues cause hypoglycemia. This treatment may increase the risk of hypoglycemia when used with insulin or an insulin secretagogue. So, a reduced dose of insulin or insulin secretagogue may be needed to scale down the probability of hypoglycemia when these agents are used along with Inpefa.
- Those treated with sotagliflozin presenting with tenderness, pain, erythema, or swelling in the genital area, together with fever or malaise, need to be evaluated for necrotizing fasciitis. If suspected, initiate treatment promptly with broad-spectrum antibiotics and, in case necessary, surgical debridement. Discontinue therapy, precisely monitor blood glucose levels, and provide relevant alternative therapy for heart failure.
- Inpefa 200 mg tablet increases the probability of genital mycotic infections. Individuals with a known history of genital mycotic infections area bit more prone to genital mycotic infections. Monitor and treat them appropriately.
- Do not monitor glucose levels with urine glucose tests as SGLT2 inhibition may increase urinary glucose excretion and will cause positive urine glucose tests. Use substitute methods to monitor glucose levels.
- Do not monitor glucose levels with 1,5-AG assay as measurements of 1,5-AG are unreliable in evaluating glucose levels in those taking SGLT2 inhibitors. Use substitute ways to monitor glucose levels.
- Use of this medicinal product is not recommended during the second as well as third trimesters of pregnancy, nor while breastfeeding.
What documents are required to import INPEFA to India?
INPEFA (sotagliflozin) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
How does the order be confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
Is INPEFA available in India?
INPEFA (sotagliflozin tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Inpefa in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
INPEFA can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Pune, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Goa, and Lucknow, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of INPEFA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Inpefa 200 mg/400 mg price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the INPEFA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Inpefa®?
Sotagliflozin is a Generic Name for the trade name drug Inpefa®.
What is the Manufacturer’s Name of Inpefa®?
Inpefa® is manufactured by Lexicon Pharmaceuticals, Inc.
Is Inpefa® approved by the FDA?
Yes, Inpefa® is approved by the FDA. Date of first approval: May 26, 2023.
Where can I get Inpefa® at the best price in India?
To get the best Inpefa price in India, kindly connect with the Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Inpefa®, a medical prescription is required from a treating physician.
What is the dosage and form of Inpefa® supplied?
Inpefa® is supplied as Tablets: 200 mg and 400 mg for oral administration.
What are the most common side effects of Inpefa®?
The most common side effects of Inpefa® are diarrhea, urinary tract infection, volume depletion, and hypoglycemia.
How much does Inpefa® cost in India?
The cost of Inpefa in India can vary. In order to procure this medicine legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Inpefa®?
Store the tablets of Inpefa® at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Inpefa® online in India?
Yes, one can buy Inpefa online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Inpefa® is not (yet) registered or available in their country. We can help facilitate the supply of Inpefa® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.